Adzynma Coverage for Congenital Thrombotic Thrombocytopenic Purpura
Customize your policy alerts
Sign up for Molina Healthcare Policy C27325-A alerts
Get alerted when Policy C27325-A changes without checking for updates manually.
Monitor payer policy activity
This policy governs coverage and prior authorization for intravenous Adzynma as prophylactic or on-demand enzyme replacement therapy for congenital thrombotic thrombocytopenic purpura in adult and pediatric members. Coverage requires documented diagnosis, laboratory and genetic confirmation, treatment planning, specialist involvement, and response at renewal.
No material clinical or coverage changes in this revision.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.